GRA2405
/ Guangzhou Respiratory Drug Engineering Technology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 23, 2026
Phase I clinical study on the safety and tolerability of GRA2405 Powder For Inhalation in healthy adults and patients with Chronic Obstructive Pulmonary Disease
(ChiCTR)
- P1 | N=103 | Sponsor: No. 28, Qiaozhong Middle Road, Liwan District, Guangzhou; First Affiliated Hospital of Guangzhou Medical University
New P1 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1